Rheumatoid arthritis (RA) is a chronic inflammatory disease that is characterized by synovial inflammation, progressive bone erosion, and cartilage destruction (1) . Development of chronic, systemic inflammation is a central characteristic of RA that drives the emergence of pathologic disease features; however, the mechanisms underlying the interplays between aberrant matrix regulation and inflammation remain incompletely described (2) .
Members of the ADAMTS family consist of extracellular proteases with a precisely ordered modular organization that includes at least one thrombospondin type I (TSP-1) repeat (3) (4) (5) . ADAMTS-12, an ADAMTS family member sharing a structure similar to ADAMTS-7 (3, 4) , is expressed in the musculoskeletal system, placenta, and fetal lungs (6) . ADAMTS-12 has been reported to play an important role in various biologic processes, including inflammation, arthritis, atherosclerosis, cancer, and angiogenesis (6) (7) (8) (9) (10) (11) (12) .
ADAMTS-12 was recently identified as an RA susceptibility gene (13) . Specifically, the rs10461703 single-nucleotide polymorphism was found to correlate with RA incidence. Moreover, ADAMTS-12 was found to be significantly increased in the cartilage and synovium of RA patients (14, 15) . Importantly, ADAMTS-12 is necessary for regulating normal inflammation through inducing neutrophil apoptosis (16) , and deletion of ADAMTS-12 leads to enhanced allergeninduced inflammation and airway hyperresponsiveness (17) . Interestingly, the release of interleukin-4 (IL-4), IL-5, IL-13, and IL-33 is notably increased in allergenchallenged ADAMTS-12-deficient mice compared to their control littermates (17) .
Given that inflammation plays a critical role in RA and that ADAMTS-12 is an RA-and inflammation-associated gene, we aimed to determine whether ADAMTS-12 plays a role in the pathogenesis of RA and to define the mechanisms involved.
MATERIALS AND METHODS
Animals. All animal studies were performed in accordance with institutional guidelines and with approval from the Institutional Animal Care and Use Committee of New York University. Twelve-week-old male mice were used in the experiments. ADAMTS-12-deficient mice on a B6 background were backcrossed at least 10 times before the mice were used for the experiments. Each group contained at least 6 mice, and the experiments were replicated 3 times unless otherwise stated.
Collagen-induced arthritis (CIA) mouse model. The CIA mouse model was established as previously described (18) . All steps were performed on ice or at 4°C in the dark to avoid the degradation of type II collagen (CII). A total of 100 lg chick CII was emulsified with an equal volume of Freund's complete adjuvant (CFA) containing 4 mg/ml heat-denatured mycobacterium (all from Chondrex). A total of 0.1 ml of the chick CII-CFA mixture was intradermally injected into 12-week-old male ADAMTS-12-deficient knockout (KO) mice or wild-type (WT) mice on day 0; injections were performed at a site~1.5 cm distal from the base of the tail. A booster, comprising 100 lg chick CII emulsified with an equal volume of Freund's incomplete adjuvant (Chondrex), was intradermally applied on day 21.
The arthritis clinical score was evaluated using the following criteria: 0 = no evidence of erythema and swelling, 1 = erythema and mild swelling confined to the tarsals or ankle joint, 2 = erythema and mild swelling extending from the ankle to the tarsals, 3 = erythema and moderate swelling extending from the ankle to the metatarsal joints, and 4 = erythema and severe swelling encompassing the ankle, foot, and digits, or ankylosis of the limb. CIA was considered to have been induced when the score reached >1 in more than 2 limbs or >2 in more than 1 limb. Incidence was taken as equal to the ratio of CIA mice to the total number of mice exposed to the emulsion injections, multiplied by 100.
To determine whether connective tissue growth factor (CTGF) could mitigate the inflammation seen in ADAMTS-12-deficient mice with CIA, commercially available human IgG or CTGF antibody (FG-3019; FibroGen) was intraperitoneally administered at 30 mg/kg body weight twice per week for 6 weeks beginning at 3 weeks following the initial primary immunization.
Osteoclast differentiation. Osteoclastogenesis was induced as previously reported (19) . Briefly, bone marrow cells were collected from WT or ADAMTS-12-deficient mice. After that, cells were suspended in prepared culture medium consisting of a-minimum essential medium (a-MEM) with L-glutamine, penicillin, streptomycin, and heat-inactivated 10% fetal bovine serum, supplemented with 10 ng/ml macrophage colony-stimulating factor (M-CSF). Then the cells were incubated at 37°C overnight. On the next day, the nonadherent cells (bone marrow-derived macrophages [BMDMs]) were collected and seeded in 96-well plates for 7 days with 10 ng/ml M-CSF. Tartrate-resistant acid phosphatase (TRAP) staining was used to determine osteoclast formation. Briefly, the cells were fixed with formalin and processed with regular TRAP staining. Red coloration indicated TRAP-positive cells. TRAPpositive multinucleated cells with >3 nuclei visualized by light microscopy were recorded as osteoclasts.
Yeast 2-hybrid (Y2H) assay. Y2H assay was performed as previously described (20) . Co-transformation of plasmids carrying ADAMTS-12 mutants fused with the VP16 transactivation domain and plasmids expressing CTGF fused with Gal4 binding domain was performed in yeast strain CG1945. Interaction was evaluated on the basis of the growth of cotransformants on selective media lacking tryptophan, leucine, and histidine in the presence of 5 mmoles/liter 3-amino-1,2, 4-triazole. The interaction was also verified by color change of co-transformants due to b-galactosidase activity converting X-Gal substrate into a blue product.
Statistical analysis. Results were expressed as the mean AE SD. For comparison of treatment groups, we performed Mann-Whitney unpaired t-tests, paired t-tests, and (where appropriate) one-or two-way analysis of variance. P values less than 0.05 were considered significant.
Detailed protocols and other procedures, including micro-computed tomography (micro-CT), histologic analysis, immunostaining, real-time polymerase chain reaction (PCR), generation of CTGF-deficient RAW 264.7 macrophages, coimmunoprecipitation, and Western blotting, are provided in the Supplementary Methods and Supplementary Figure 1 
RESULTS
Deficiency of ADAMTS-12 and acceleration of inflammatory arthritis. To determine the role of endogenous ADAMTS-12 in vivo in the pathogenesis of inflammatory arthritis, we investigated the clinical and histopathologic features of ADAMTS-12-deficient mice and their control littermates in a mouse model of CIA. Accelerated disease onset, as well as significant increases in the arthritis severity score and arthritis incidence, were observed in ADAMTS-12-deficient mice as compared to control littermates ( Figures 1A  and B) . Representative images demonstrated that ADAMTS-12-deficient mice developed more severe paw swelling than WT mice ( Figure 1C ). Micro-CT imaging revealed more bone destruction in ADAMTS-12-deficient mice ( Figure 1D ). Additionally, ADAMTS-12-deficient mice exhibited significantly less bone volume to total volume compared to WT mice ( Figure 1D ). Histologic analysis of whole ankle joints demonstrated a Given that inflammatory arthritis is a systemic disease (19), we collected sera from mice with CIA to investigate the level of inflammation-related cytokines by enzyme-linked immunosorbent assay. Data indicated that levels of proinflammatory cytokines in ADAMTS-12-deficient mice, including tumor necrosis factor (TNF), IL-1b, IL-6, and IL-17, were significantly higher than those in control littermates ( Figures 1J-M) . Interestingly, the level of IL-10, an antiinflammatory cytokine, was significantly lower in ADAMTS-12-deficient mice than that in WT mice ( Figure 1N ). These data indicate that ADAMTS-12-deficient mice exhibit enhanced release of proinflammatory and reduced secretion of antiinflammatory cytokines in the CIA model. Given that CIA is also associated with anticollagen IgG responses, we investigated whether ADAMTS-12 deficiency affected anticollagen IgG response. The results revealed that ADAMTS-12-deficient mice with CIA generated a similar level of collagen-specific IgG, as compared to WT mice with CIA ( Figure 1O ), suggesting that increased susceptibility of ADAMTS-12-deficient mice to CIA is not the consequence of an increased anticollagen IgG response. Values are the mean AE SD. * = P < 0.05; ** = P < 0.01; *** = P < 0.001 versus the control WT group. Color figure can be viewed in the online issue, which is available at http://onlinelibrary.wiley.com/doi/10.1002/art.40552/abstract.
Deficiency of ADAMTS-12 and accelerated osteoclastogenesis. In the pathogenesis of inflammatory arthritis, osteoclastogenesis accompanies bone destruction. Accordingly, we next investigated the role of ADAMTS-12 in osteoclastogenesis during the inflammatory arthritis process. For this purpose, ankle joints collected from mice with CIA were used for TRAP staining; more osteoclasts were observed in ADAMTS-12-deficient mice compared to WT mice (Figure 2A ). To further confirm this finding and investigate the mechanism involved, we examined the effects of ADAMTS-12 on osteoclastogenesis in vitro. We isolated primary bone marrow cells and induced differentiation of these cells into osteoclasts. TRAP staining demonstrated that ADAMTS-12 deficiency led to significantly more TRAP-positive osteoclasts when compared to control mice ( Figure 2B ). In accordance with this, ADAMTS-12 deficiency significantly up-regulated the expression of marker genes of osteoclastogenesis, such as TRAP, cathepsin K, and calcitonin receptor (Figures 2C-E) . Collectively, these findings demonstrated that ADAMTS-12 deficiency resulted in enhanced osteoclastogenesis in the pathogenesis of inflammatory arthritis.
ADAMTS-12 interacts with and cleaves CTGF. It is known that CTGF plays a proinflammatory and pro-osteoclastogenesis role in the pathogenesis of inflammatory arthritis (21) . The facts that 1) ADAMTS-7 and ADAMTS-12 share similar structure (12) , and that 2) ADAMTS-7 binds and digests CTGF (20) prompted us to investigate whether ADAMTS-12 exerts its role in inflammatory arthritis through interacting with CTGF. To address this issue, we cotransfected CTGF and ADAMTS-12 into 293T cells and performed a co-immunoprecipitation assay. As indicated in Figure 3A , a specific CTGF band was immunoprecipitated by anti-CTGF Figure 3 . ADAMTS-12 is specifically associated with connective tissue growth factor (CTGF). A, Co-immunoprecipitation (IP) assays with Western blotting (WB), revealing specific associations of ADAMTS-12 with CTGF in immune complexes precipitated with CTGF antibody (Ab) from protein lysates of 293T cells that were cotransfected with CTGF (a) and ADAMTS-12 (b) expression plasmids. B, CTGF interaction with ADAMTS-12 or truncated forms in yeast 2-hybrid analyses, shown in a schematic representation of ADAMTS-12 and its truncation mutants. Interaction was evaluated by color change of cotransformants in the colony lift assay resulting from b-galactosidase-mediated conversion of X-Gal substrate into a blue product. TSP = thrombospondin type 1. C, Western blotting of CTGF. CTGF was transfected into 293T cells (1) or CTGF and ADAMTS-12 were cotransfected into 293T cells (2) . Forty-eight hours later, cell lysates were prepared and CTGF processing was analyzed by immunoblotting with anti-CTGF antibody. antibodies in CTGF and ADAMTS-12-cotransfected cells; ADAMTS-12 bands were also immunoprecipitated by anti-CTGF antibodies under the same conditions (Figure 3A, part b) , suggesting that ADAMTS-12 specifically associates with CTGF. We next sought to identify the domains of ADAMTS-12 required for binding to CTGF. For this purpose, a series of truncated mutants of ADAMTS-12 were subcloned into a yeast expression pPC86 vector, and a Y2H assay was performed. Like ADAMTS-7, which has been reported to interact with CTGF (20) , the C-terminal region containing a mucin domain (also called spacer-2) and TSP-1 repeats 5-8 of ADAMTS-12 were required and sufficient for interaction with CTGF ( Figure 3B ).
More importantly, we observed the accumulation of CTGF fragments in Western blot analysis using a rabbit polyclonal antibody that recognized C-terminal CTGF protein ( Figure 3C ) in the lysate collected from cotransfected 293T cells, indicating binding and degradation of CTGF by ADAMTS-12 in mammalian cells. Furthermore, immunohistochemistry staining demonstrated that ADAMTS-12 was mainly expressed in cartilage, and CTGF was expressed in cartilage and synovium (Figure 3D) . In addition, the CTGF expression was highly up-regulated in ADAMTS-12-deficient CIA mice as compared to WT mice with CIA ( Figure 3E ). Serum CTGF levels were also markedly increased in ADAMTS-12-deficient CIA mice as compared to WT mice with CIA (Figure 3F) . Taken together, all of the in vitro and in vivo evidence indicated that ADAMTS-12 interacted with and cleaved CTGF, and that ADAMTS-12 deficiency caused accumulation of CTGF during inflammatory arthritis.
Deletion of ADAMTS-12 enhances CTGFmediated inflammatory responses. It is known that CTGF is a key proinflammatory mediator in fibroblast-like synoviocytes (FLS) (22) . Additionally, in FLS, CTGF could promote expression of proinflammatory mediators in the presence of IL-1b (23) . Moreover, CTGF could enhance IL-1b-mediated signaling pathways. Given the fact that ADAMTS-12 interacts with and cleaves CTGF, we next investigated whether ADAMTS-12 regulates CTGFmediated inflammatory signaling. To address this issue, we isolated BMDMs from ADAMTS-12-KO mice and their control littermates and cultured the cells in the absence or presence of IL-1b with or without CTGF. As indicated in Figure 4A , IL-1b activated JNK, p38, and NF-jB signaling, and CTGF further enhanced IL-1b-mediated inflammatory signaling pathways in WT BMDMs, which is consistent with previous findings (23, 24) . Interestingly, in ADAMTS-12-deficient mouse BMDMs, the phosphorylation of these molecules was enhanced at each time point compared to WT mouse BMDMs. In addition, ADAMTS-12 deficiency led to increased expression of nitric oxide synthase 2 (NOS-2), an inflammation marker, in the presence of CTGF (Figure 4B) . To further investigate the mechanism involved, we cultured the BMDMs with various stimuli for 6 hours, followed by real-time PCR. IL-1b could up-regulate the expression of inflammatory factors such as IL-6, NOS-2, and COX-2. The up-regulation of these genes was further enhanced in the presence of CTGF. Of note, the transcription level of IL-6, NOS-2, and COX-2 was significantly higher, in the absence or presence of CTGF, in ADAMTS-12-deficient mouse BMDMs as compared to WT mouse BMDMs in response to IL-1b stimulation ( Figures 4D and E) . Additionally, the transcript levels of Figure 5 . ADAMTS-12-mediated signaling depends on connective tissue growth factor (CTGF) during inflammation. A, Generation of CTGFdeficient (CTGF-def) RAW 264.7 cells using the clustered regularly interspaced short palindromic repeat/Cas9 technique. Expression of CTGF was determined by immunoblotting. B and C, Wild-type (WT) or CTGF-def RAW 264.7 macrophages were transfected with pcDNA-ADAMTS12 (pcDNA-TS12) for 48 hours, and cells were then treated with or without interleukin-1b (IL-1b) for the indicated time. Cells were isolated to determine the phosphorylation of p65, p38, and JNK and the expression level of TS12 (B), or the expression of type 2 nitric oxide synthase (NOS-2) and TS12 (C) by immunoblotting. D-F, WT or CTGF-def RAW 264.7 cells were transfected with pcDNA-TS12 for 48 hours, and cells were then treated with or without IL-1b. Transcription expression levels of IL-6 (D), NOS-2 (E), and COX-2 (F) were evaluated by real-time polymerase chain reaction. Values are the mean AE SD. * = P < 0.05; ** = P < 0.01 versus control group. The experiments were repeated 3 times. IL-6, NOS, and COX-2 were significantly higher with a combination of CTGF and IL-1b stimulation than with IL-1b stimulation alone. Collectively, these findings indicate that deficiency of ADAMTS-12 results in enhanced CTGF-mediated inflammatory responses.
CTGF is a critical mediator of ADAMTS-12 signaling during inflammation. Since loss of ADAMTS-12 increased CTGF-mediated signaling, we next investigated whether CTGF is also a critical regulator of ADAMTS-12-mediated signaling. To address this issue, we generated CTGF-deficient RAW 264.7 macrophages using the clustered regularly interspaced short palindromic repeat/ Cas9 technique, then transfected these CTGF-deficient macrophages with an ADAMTS-12 overexpression plasmid. As shown in Figure 5A , the expression of CTGF was dramatically decreased in CTGF-deficient RAW 264.7 macrophages. Interestingly, overexpression of ADAMTS-12 could decrease the activation of inflammatory signaling, such as NF-jB, p38, and JNK, in response to IL-1b. CTGF deficiency also resulted in the decreased activation of these signaling molecules, and this decrease reached an extent comparable to that observed in ADAMTS-12-overexpressing WT RAW 264.7 macrophages. More importantly, overexpression of ADAMTS-12 in CTGF-deficient RAW 264.7 macrophages failed to further inhibit the activation of these signal molecules as compared to CTGF-deficient RAW 264.7 macrophages ( Figure 5B) . Accordingly, the expression of NOS-2, one of the inflammatory markers, was inhibited by overexpression of ADAMTS-12 in RAW 264.7 macrophages and CTGF-deficient RAW 264.7 macrophages at a comparable level in response to IL-1b. Overexpression of ADAMTS-12 in CTGF-deficient RAW 264.7 macrophages failed to further inhibit the Figure 5C ). In addition, the transcription levels of inflammatory markers such as IL-6, NOS-2, and COX-2 exhibited the same trend demonstrated at the protein level for NOS-2 in response to IL-1b (Figures 5D-F) . Taken together, these results suggest that CTGF is a critical mediator of ADAMTS-12-mediated signaling during inflammation. In other words, ADAMTS-12 exerts its inhibition of inflammation at least in part through, regulating CTGF turnover.
Blocking of CTGF attenuates inflammatory arthritis in ADAMTS-12-deficient mice with CIA. To determine whether the enhanced inflammation in ADAMTS-12-deficient mice with CIA resulted from accumulation of CTGF, we injected CTGF antibody, FG-3019, into ADAMTS-12-deficient mice after CIA onset. The arthritis score in ADAMTS-12-deficient mice treated with FG-3019 was significantly reduced, to a similar level as observed in WT mice with CIA ( Figure 6A ). Moreover, histologic analysis indicated that FG-3019 significantly reduced inflammation and abrogated further tissue destruction in ADAMTS-12-deficient mice with (Figures 6B and C) . Specifically, the scores for erosion, synovitis, and pannus formation were significantly decreased in the presence of FG-3019 in ADAMTS-12-deficient mice ( Figures 6D-F) . These results show that ADAMTS-12 deficiency led to accelerated inflammatory arthritis, and blocking CTGF could attenuate the elevated inflammatory response in these mice. Cumulatively, these findings suggest that processing of CTGF by ADAMTS-12 could limit inflammation.
DISCUSSION
RA is a chronic autoimmune disorder in which inflammatory cytokines play a critical role (25) , and antiinflammatory drugs are widely used to improve the disease symptoms (26) . ADAMTS-12 was shown to be required for maintaining inflammation in a model of allergen-induced airway disease (17) . Previous data indicated that ADAMTS-12 was an RA susceptibility gene (13) , and that the level of ADAMTS-12 was significantly increased in RA patients (14, 15) , suggesting that ADAMTS-12 might also play a role in RA pathology. Indeed, in this study we provide comprehensive evidence indicating that ADAMTS-12 plays a critical role in inflammatory arthritis in mice. We found that deletion of ADAMTS-12 in genetically modified mice leads to enhanced inflammation in the CIA model. Higher clinical scores of arthritis and disease incidence in ADAMTS-12-deficient mice indicated that ADAMTS-12-deficient mice are more susceptible to CIA. Given that inflammatory arthritis involves cartilage destruction, bone erosion, and synovitis, we examined the histologic changes to bone and cartilage after deleting ADAMTS-12. Data suggested that loss of ADAMTS-12 resulted in more cartilage and bone loss. Importantly, synovial inflammation and pannus formation were significantly increased in ADAMTS-12-deficient mice. Additionally, it is wellknown that inflammatory cytokines such as TNF, IL-1, IL-6, and IL-17 are up-regulated, and the antiinflammatory cytokine, IL-10, is down-regulated, in the pathogenesis of RA. Interestingly, our data showed that loss of ADAMTS-12 resulted in increased levels of inflammatory cytokines and decreased levels of antiinflammatory cytokine. All of these data suggest that ADAMTS-12 is required for limiting inflammatory arthritis.
Even though the potential involvement of ADAMTS-12 in arthritis was suggested in previous studies (3, 6, 14, 15, (27) (28) (29) , the elucidation of a detailed mechanism was not possible without defining its substrate. Importantly, ADAMTS-7 and ADAMTS-12 share a similar structure and form one ADAMTS subgroup. The high similarity between ADAMTS-7 and ADAMTS-12 suggests that they could share a similar substrate. Indeed, both of them were reported to be able to interact with and digest cartilage oligomeric matrix protein (COMP) (14, 15, 27, (30) (31) (32) (33) . Interestingly, it was recently reported that ADAMTS-7 could directly interact with and processes CTGF. CTGF, also called CCN2, belongs to the CCN family and is associated with angiogenesis, fibrosis, atherosclerotic blood vessels, and erosive arthritis lesions (34) . It is well accepted that CTGF contributes to the proinflammatory and proatherogenic state in patients with RA (21, 35, 36) . Given the importance of CTGF in RA and the similar structure between ADAMTS-7 and ADAMTS-12, we hypothesized that ADAMTS-12 also interacts with and cleaves CTGF. Both Y2H and co-immunoprecipitation assays indicated that ADAMTS-12 and CTGF could bind together; the C-terminal mucin and TSP motifs of ADAMTS-12 were required and sufficient for binding CTGF. After overexpression of ADAMTS-12, the expression of full-length CTGF was reduced and the expression of CTGF fragments was increased. Importantly, CTGF appeared to accumulate in the synovium of ADAMTS-12-deficient mice with inflammatory arthritis, suggesting that ADAMTS-12 is involved in CTGF turnover and ADAMTS-12 deficiency may slow CTGF clearance.
CTGF is a well-studied protein in arthritis; however, its roles in osteoarthritis (OA) and inflammatory arthritis differ. OA is considered to be a degenerative disease characterized by cartilage destruction, subchondral bone sclerosis, synovial inflammation, and osteophyte formation (37) . Even though it is well accepted that cartilage, plasma, and synovial fluid CTGF concentrations positively correlate with radiographic severity in OA (38) , studies have yielded conflicting results regarding its role in this disease. Specifically, some studies using genetically modified mouse models and in vitro assays have demonstrated a protective role of CTGF against articular cartilage degeneration in OA progression through regulating chondrocyte differentiation and proliferation (39) (40) (41) (42) (43) . However, given the importance of synovial lining cells in OA progression, some studies suggested that CTGF promoted inflammation and cartilage damage in the pathogenesis of OA (23, (44) (45) (46) .
Regardless of the controversy in OA, studies have consistently demonstrated that CTGF strongly promoted a catabolic effect in inflammatory arthritis progression (21, 47) . The different roles of CTGF in OA and inflammatory arthritis may be due to its different roles in different cells and distinct microenvironments. In inflammatory arthritis progression, synovial fibroblasts play a critical role. In both OA and RA fibroblast cells, CTGF could up-regulate proinflammatory cytokines such as IL-6 and monocyte chemoattractant protein 1 to accelerate the disorder (45, 46, 48) . Interestingly, studies have indicated that blocking CTGF largely ameliorated inflammatory arthritis in multiple murine models (21, 35, 48) . In the present study, we found that CTGF enchanced expression of proinflammatory mediators such as IL-6, NOS-2, and COX-2 in response to IL-1b stimulation, and more importantly, ADAMTS-12 deficiency resulted in further enhanced up-regulation of these proinflammatory cytokines in response to IL-1b. Additionally, MAPK and NF-jB signaling pathways involved in inflammation were enhanced after deletion of ADAMTS-12. On the other hand, overexpression of ADAMTS-12 reduced CTGF-induced inflammation (see Supplementary  Figure 1 , available on the Arthritis & Rheumatology web site at http://onlinelibrary.wiley.com/doi/10.1002/art.40552/ abstract). ADAMTS-12 constraint of inflammation was lost in CTGF-deficient RAW 264.7 macrophages cells ( Figure 5 ).
Our data suggested that ADAMTS-12 deficiency enhanced inflammatory arthritis at least in part via the CTGF pathway. To further confirm this, we injected FG-3019 into ADAMTS-12-deficient mice with CIA. FG-3019 effectively rescued the symptoms and pathologic changes caused by loss of ADAMTS-12, whereas it failed to further suppress inflammation in WT CIA mice ( Figure 6 ). These results, together with the finding that blocking CTGF improved the arthritis in ADAMTS-12-deficient mice but only to the level of severity seen in WT mice with CIA, suggest that targeting CTGF could be an effective approach for treating inflammatory arthritis under conditions in which CTGF levels are significantly elevated, for instance, in the absence or deficiency of ADAMTS-12. It should be noted that the failure of CTGF antibody to suppress inflammation in WT mice with CIA may also be due to an insufficient dose and/or frequency of antibody administration, as well as the genetic background of the mice used in the current study.
Besides inflammation, osteoclastogenesis also plays an important role in inflammatory arthritis by promoting bone erosion. Additionally, proinflammatory cytokines effectively promote osteoclast differentiation (19) . Accordingly, we examined whether ADAMTS-12 was involved in osteoclast differentiation. The present study indicated that deletion of ADAMTS-12 caused accelerated osteoclast formation both in vivo and in vitro. Considering that CTGF strongly promoted osteoclastogenesis (36) and there is an interaction between CTGF and ADAMTS-12, the data suggest that ADAMTS-12 deficiency caused enhanced osteoclastogenesis at least partially through the CTGF pathway. Collectively, these findings suggest that in inflammatory arthritis progression, ADAMTS-12-deficient mice might lose the ability for inactivating CTGF, leading to enhanced susceptibility. Even though ADAMTS-12 and ADAMTS-7 share similar structure and substrate(s), the metalloproteinases play different roles in inflammatory arthritis. Previous data indicated overexpression of ADAMTS-7 promoted inflammation and cartilage destruction in transgenic ADAMTS-7 mice with CIA (49). Perhaps ADAMTS-7 exhibits better efficacy in degrading COMP relative to ADMATS-12. Furthermore, the transgenic mouse model may create an artificial environment that cannot fully demonstrate the real mechanism. Additionally, ADAMTS-7 is regarded as a proinflammatory metalloproteinase since it forms a positive loop with TNF (50) . Although ADAMTS-7 could bind and cleave CTGF, TNF enhances CTGF production in synovial fibroblasts while inhibiting CTGF in chondrocytes. Therefore, the true CTGF levels in ADAMTS-7-deficient mice are still unknown, and the role of ADAMTS-7 in inflammatory arthritis remains to be delineated (48) .
In conclusion, ADAMTS-12 appears to be a critical regulator of inflammatory arthritis, at least in part via interaction with and inactivation of CTGF. These findings not only provide novel insights into the role of ADAMTS-12 in the pathogenesis of inflammatory arthritis in vivo, but may also lead to the development of novel therapeutic intervention strategies for RA.
